Robert  Glassman net worth and biography

Robert Glassman Biography and Net Worth

Director of Pharvaris

Dr. Glassman has been a director since January 2021. Since July 2022, Dr. Glassman served as the Executive Vice President, Search & Evaluation at Enavate Sciences, a $600M private equity fund that is a subsidiary of Patient Square Capital. Dr. Glassman also serves as a board member for Umoja and EluraBio and is an advisor at Centrexion.

Dr. Glassman is an industry veteran with nearly 30 years of healthcare leadership and investment experience. Most recently, he was a venture partner in public equity at OrbiMed Advisors, returning to the firm after serving as a private equity partner. Previously, he worked as a senior investment banking professional for over seventeen years across Credit Suisse, Merrill Lynch, Bank of America, most recently serving as Vice Chairman of the Global Health Care Investment Banking division at Credit Suisse. Earlier in his career, Dr. Glassman oversaw healthcare investments at Merrill Lynch Global Private Equity and was a consultant within McKinsey & Company’s Pharmaceutical and Medical Products practice. Dr. Glassman was a board-certified hematologist-oncologist and remains on the faculty of Weill Cornell as a Clinical Assistant Professor of Medicine. He also spent several years as a basic science investigator at Rockefeller University in the laboratory of Hidesaburo Hanafusa, where he received Howard Hughes Medical Institute and American Cancer Society awards. Dr. Glassman earned his A.B. from Harvard College and an M.D. from Harvard Medical School.

What is Robert Glassman's net worth?

The estimated net worth of Robert Glassman is at least $316.31 thousand as of May 15th, 2026. Glassman owns 10,500 shares of Pharvaris stock worth more than $316,313 as of June 3rd. This net worth approximation does not reflect any other assets that Glassman may own. Learn More about Robert Glassman's net worth.

How do I contact Robert Glassman?

The corporate mailing address for Glassman and other Pharvaris executives is , , . Pharvaris can also be reached via phone at 31-71-203-6410 and via email at [email protected]. Learn More on Robert Glassman's contact information.

Has Robert Glassman been buying or selling shares of Pharvaris?

During the last quarter, Robert Glassman has sold $298,200.00 of Pharvaris stock. Most recently, Robert Glassman sold 10,000 shares of the business's stock in a transaction on Friday, May 15th. The shares were sold at an average price of $29.82, for a transaction totalling $298,200.00. Following the completion of the sale, the director now directly owns 10,500 shares of the company's stock, valued at $313,110. Learn More on Robert Glassman's trading history.

Who are Pharvaris' active insiders?

Pharvaris' insider roster includes Elisabeth Bjork (Director), Robert Glassman (Director), Anne Lesage (Chief Early Development Officer), Anne Lesage (Insider), Peng Lu (Chief Medical Officer), Berndt Modig (Chief Executive Officer, Director (CH)), Viviane Monges (Director), David Nassif (CFO), Anna Nijdam (Insider), and Wim Souverijns (Insider). Learn More on Pharvaris' active insiders.

Are insiders buying or selling shares of Pharvaris?

In the last twelve months, insiders at the sold shares 24 times. They sold a total of 209,948 shares worth more than $6,268,140.96. The most recent insider tranaction occured on May, 22nd when insider Anna Nijdam sold 5,501 shares worth more than $169,100.74. Learn More about insider trades at Pharvaris.

Information on this page was last updated on 5/22/2026.

Robert Glassman Insider Trading History at Pharvaris

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/15/2026Sell10,000$29.82$298,200.0010,500View SEC Filing Icon  
See Full Table

Robert Glassman Buying and Selling Activity at Pharvaris

This chart shows Robert Glassman's buying and selling at Pharvaris by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pharvaris Company Overview

Pharvaris logo
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
Read More

Today's Range

Now: $30.14
Low: $28.80
High: $30.50

50 Day Range

MA: $28.86
Low: $25.34
High: $32.94

2 Week Range

Now: $30.14
Low: $15.91
High: $33.33

Volume

703,962 shs

Average Volume

233,293 shs

Market Capitalization

$1.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A